Naveen Singri, MD
Nephrology · Columbus, OHNPI 1215994744
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Lundbeck LLC at 52.8% of the total. Reporting peaked in 2019 at $8,244 and has fallen 94.4% since, to $461 in 2025. Among nephrology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 147 payments — averaging $77.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$6K
- Outset Medical Inc$3K
- GSK$353
- Aurinia Pharma U.S., Inc.$332
- Bayer$246
- Boehringer Ingelheim$201
- plus $2K from 24 others
Across 13 payments — averaging $8976.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alnylam Pharmaceuticals Inc.$117K
What the payments were for
- Consulting fees$2,67323%
- Speaking & faculty fees$5,85051%
- Food & beverage$2,81325%
- Education$921%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 13 | $6,038 |
| Outset Medical Inc | 3 | $2,685 |
| GSK | 18 | $353 |
| Aurinia Pharma U.S., Inc. | 6 | $332 |
| Bayer | 6 | $246 |
| Boehringer Ingelheim | 7 | $201 |
| AstraZeneca(2 entities) | 12 | $188 |
| Fresenius USA Marketing, Inc. | 6 | $169 |
| Amgen(2 entities) | 8 | $161 |
| Calliditas Therapeutics US Inc. | 1 | $114 |
| Novo Nordisk | 5 | $110 |
| Otsuka America Pharmaceutical, Inc. | 5 | $108 |
| Novartis | 4 | $106 |
| Vifor Pharma, Inc. | 6 | $103 |
| Travere Therapeutics, Inc. | 20 | $52 |
| AMAG Pharmaceuticals, Inc. | 3 | $48 |
| Daiichi Sankyo Inc. | 3 | $48 |
| Akebia Therapeutics Inc | 3 | $48 |
| Ardelyx, Inc. | 2 | $39 |
| Baxter Healthcare | 2 | $38 |
| Mallinckrodt Hospital Products Inc. | 2 | $36 |
| Sanofi | 2 | $33 |
| OPKO Pharmaceuticals, LLC | 2 | $32 |
| Johnson & Johnson | 2 | $26 |
| Shire North American Group Inc | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $21 |
| Mannkind Corporation | 1 | $20 |
| Apellis Pharmaceuticals, Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,427 in reported general payments places this provider in the 90th percentile of 450 nephrology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 154 | $128,141 |
| VelphoroSucroferric Oxyhydroxide | 19 | $48,195 |
| JardianceEmpagliflozin | 45 | $39,929 |
| Clonidine | 37 | $7,595 |
| ProcritEpoetin Alfa | 12 | $6,302 |
| DapagliflozinDapagliflozin Propanediol | 11 | $5,863 |
| Sevelamer Carbonate | 14 | $3,966 |
| Potassium Citrate ErPotassium Citrate | 19 | $3,690 |
| Eplerenone | 26 | $3,383 |
| Nifedipine ErNifedipine | 74 | $2,117 |
| Klor-Con M20Potassium Chloride | 11 | $1,651 |
| Valsartan | 77 | $1,479 |
| Calcitriol | 98 | $1,423 |
| Bumetanide | 29 | $1,373 |
| Calcium Acetate | 22 | $1,287 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $188 | $128,141154 claims |
| Fresenius USA Marketing, Inc.Velphoro | $169 | $48,19519 claims |
| Boehringer IngelheimJardiance | $201 | $39,92945 claims |
| Johnson & JohnsonProcrit | $26 | $6,30212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 450 nephrology providers in Ohio.
Other nephrology in Columbus
- Brad RovinColumbus$379K
- Samir ParikhColumbus$145K
- Isabelle AyoubColumbus$116K
- Anil AgarwalColumbus$99K
- Karim AttiaColumbus$43K
- Rima KangColumbus$28K
- Salem AlmaaniColumbus$21K
- Todd PesaventoColumbus$20K
- Jessica GrecoColumbus$11K
- Jason ProsekColumbus$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.